What do investors look for in medical device start-ups? What value do they provide to entities like CBID, a biodesign research center and provider of a cutting-edge master’s program in biodesign? To gain more insight into where academia meets bio-innovation, I spoke to Professor Yazdi.
“So...who’s ever been stressed at Stanford?”
I half-jokingly asked this question to a group of undergrads, PhD students, and faculty on a rainy Thursday night. It was the middle of the quarter, right before the dreaded “midterm season.” With upcoming deadlines for projects and tests, while balancing extracurriculars and friendships, students can feel overwhelmed by all of their commitments.
Like many Stanford students, Anjini came to college excited but also overwhelmed by the breadth of opportunities. “In the beginning, it can be extremely difficult finding one’s own niche,” she says, “Ultimately, I wanted to pursue what I truly enjoyed.”
Meet Autumn! She is a member of Stanford Students in Biodesign’s conference team and is currently a sophomore studying Bioengineering. This New Yorker has been recognized by Forbes, Huffington Post, and Teen Vogue as a rising innovator and an inspiration for girls and women alike as she balances being a biomedical researcher and model.
At the end of the Stanford Biomedical Engineering Society Spring Industry Panel, Dr. Eric Schuur told me, “You get a head-start hearing these things when you are young.” Indeed, over the past hour—a discussion panel organized by BMES Industry Vice President Alex Maben and BMES Industry Officer Amelia Traylor—three speakers from biotechnological and biocomputational companies voiced insights on essential undergraduate skills, post-undergrad education, and workplace culture.
Emeritus Professor Bill Durham is a legend in Human Biology. A former graduate of Stanford, Bill has been with the Human Biology Program since 1977, where he has carried out research on environmental anthropology, the challenges of sustainable development, and conservation issues in Galapagos. But perhaps the most surprising moment of his career came in 2001 when a friend called Bill about a rare ailment that had just been discovered in his family.
Biochemist and neurobiologist Michael Lin is developing smart biological therapies that may finally provide the “magic bullet” for cancer. He sat down with Probe Magazine to discuss his dreams and current research projects, and give a few words of advice to STEM students.